Gilead gets ball rolling on JAKs game in Japan

Gilead is gearing up for a full JAK1 launch.

Four days after submitting an NDA for their new JAK1 inhibitor for rheumatoid arthritis, filgotinib, the pharma giant has handed distribution and co-promotion rights in Japan to Eisai, should it be approved on the islands. Gilead has already submitted the drug for regulatory approval there.